TMOD-17. A NOVEL ADENOVIRAL-PERMISSIVE, IMMUNOCOMPETENT HAMSTER MODEL TO EVALUATE ONCOLYTIC ADENOVIRAL THERAPY FOR GLIOBLASTOMA

Treatment with the oncolytic adenovirus, Delta-24-RGD, resulted in dramatic tumor response in 20% of recurrent malignant glioma patients in a recent Phase I clinical trial. Studies in immunocompetent mice corroborate the patient data indicating that Delta-24-RGD effects are due to both direct tumor cell lysis and viral-mediated anti-tumor immune response. However, it is unclear why only a fraction of patients responds in this manner. Due to poor...